Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hoffman

Showing results (431-440 of 470) with videos related to

Pageof 47
Sort By:
Toxicology Letters|February 21, 2026
Dissolution of man-made vitreous fibres (MMVF) using the USP-4: Part I. Fluid choice for closed-loop configuration testsDenis V Okhrimenko, Léa Hiéronimus, John W Hoffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
Investigational New Drugs|August 7, 2012
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanomaPatrick A Ott, Richard D Carvajal, Neeta Pandit-Taskar, et al.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 25, 2020
SPOT GRADE II: Clinical Validation of a New Method for Reproducibly Quantifying Surgical Wound Bleeding: Prospective, Multicenter, Multispecialty, Single-Arm StudyDaniel J Del Gaizo, William D Spotnitz, Rachel W Hoffman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patientsDjordje Atanackovic, Nasser K Altorki, Elisabeth Stockert, et al.
Cancer Immunity|August 21, 2007
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinomaIan D Davis, Zhanqi Liu, Wayne Saunders, et al.
Nutrition Research (New York, N.Y.)|May 19, 2016
β-Hydroxy-β-methylbutyrate attenuates cytokine response during sustained military trainingJay R Hoffman, Yiftach Gepner, Jeffrey R Stout, et al.
JCI Insight|February 9, 2018
The homozygous CX3CR1-M280 mutation impairs human monocyte survivalAmanda L Collar, Muthulekha Swamydas, Morgan O'Hayre, et al.
Cancer Immunity|August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinomaIan D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
Pageof 47

Showing results (431-440 of 470) with videos related to

Sort By:
Pageof 47
Toxicology Letters|February 21, 2026
Dissolution of man-made vitreous fibres (MMVF) using the USP-4: Part I. Fluid choice for closed-loop configuration testsDenis V Okhrimenko, Léa Hiéronimus, John W Hoffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
Investigational New Drugs|August 7, 2012
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanomaPatrick A Ott, Richard D Carvajal, Neeta Pandit-Taskar, et al.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 25, 2020
SPOT GRADE II: Clinical Validation of a New Method for Reproducibly Quantifying Surgical Wound Bleeding: Prospective, Multicenter, Multispecialty, Single-Arm StudyDaniel J Del Gaizo, William D Spotnitz, Rachel W Hoffman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patientsDjordje Atanackovic, Nasser K Altorki, Elisabeth Stockert, et al.
Cancer Immunity|August 21, 2007
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinomaIan D Davis, Zhanqi Liu, Wayne Saunders, et al.
Nutrition Research (New York, N.Y.)|May 19, 2016
β-Hydroxy-β-methylbutyrate attenuates cytokine response during sustained military trainingJay R Hoffman, Yiftach Gepner, Jeffrey R Stout, et al.
JCI Insight|February 9, 2018
The homozygous CX3CR1-M280 mutation impairs human monocyte survivalAmanda L Collar, Muthulekha Swamydas, Morgan O'Hayre, et al.
Cancer Immunity|August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinomaIan D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
Pageof 47